

Extracellular vesicles of the blood-brain barrier

Ibolya E András* and Michal Toborek*

Department of Biochemistry and Molecular Biology; University of Miami School of Medicine; Miami, FL USA

Keywords: amyloid β , brain endothelial cells, blood-brain barrier, extracellular vesicles, exosomes

Extracellular vesicles (ECV), like exosomes, gained recently a lot of attention as potentially playing a significant role in neurodegenerative diseases, particularly in $A\beta$ pathology. While there are a lot of reports on ECV/exosomes derived from a variety of cell types, there is limited information on ECV/exosomes originated from brain microvascular endothelial cells forming the blood-brain barrier (BBB). In this review, we summarize the literature data on brain endothelial ECV/exosomes and present our own data on BBB-derived ECV and their possible involvement in the brain's $A\beta$ pathology. We propose that ECV/exosome release from brain endothelial cells associated with $A\beta$ affects different cells of the neurovascular unit and may be an important contributor to the $A\beta$ deposition in the central nervous system.

Introduction

Brain microvascular endothelial cells joined by tight junctions constitute the anatomical basis of the blood-brain barrier (BBB). These cells line the brain microvessels and represent the major interface between the blood and the central nervous system. They maintain the brain homeostasis by regulating BBB permeability as well as molecular and cellular traffic across the barrier.¹

The BBB, together with the neighboring cells, including pericytes, perivascular astrocytes, microglia, and neurons, forms a functional unit called the neurovascular unit. In this structural and functional module, a capillary fragment together with the associated other cell types, support several neurons. Within the neurovascular unit, there is a complex physiological and pathological cross-talk between the different cell types.² Disturbances of the BBB and neurovascular unit dysfunction are important players in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD).³ It is believed that the BBB is critical for amyloid β ($A\beta$) homeostasis and may have a role in $A\beta$ accumulation in the brain.⁴ According to the amyloid cascade hypothesis, $A\beta$ deposition in the brain may contribute to neurodegeneration.³

© Ibolya E András and Michal Toborek

*Correspondence to: Ibolya E András; Email: iandras@med.miami.edu; Michal Toborek; Email: mtoborek@med.miami.edu

Submitted: 10/23/2015; Revised: 12/04/2015; Accepted: 12/09/2015
<http://dx.doi.org/10.1080/21688370.2015.1131804>

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

Extracellular Vesicles Represent A Complex Carrier System

Extracellular vesicles (ECV) have drawn attention as being important players in a variety of neurodegenerative diseases. ECV are heterogeneous and include exosomes⁵ and other larger vesicles derived from plasma membrane shedding, e.g., microvesicles ranging in size from 100 to 1000 nm.^{6,7,8}

Exosomes are small ECV secreted by cells of approximately 30-100 nm in size. Exosomes carry diverse cellular cargo originating from the parent cell including mRNAs, miRNAs, lipids and proteins. After release, exosomes can enter the circulatory system, being carried to distant sites in the periphery, or they can act on cells in the immediate microenvironment. Exosomes reaching their target are internalized by recipient cells through endocytosis.⁹ The exosome membrane contains various proteins; some of them may be involved in exosome targeting, like tetraspanins.¹⁰ Even if they originate from the same cell, secreted extracellular vesicles may be of different sizes and may enclose various cargo-molecules,¹¹ which are considered important players in a special way of cell-cell communication. Because exosomes bud from endosomes, they contain a variety of proteins including membrane transport and fusion proteins (GTPases, annexins, flotillin) as well as tetraspanins (CD9, CD63, CD81, and CD82).¹² Marker proteins widely used to characterize exosomes include the tetraspanins CD63, CD9, or Alix.

Exosomes were shown to be released from brain cells, including neurons, glial cells, astrocytes and oligodendrocytes, and it is believed that they create a highly unique cell-cell communication system, which may play an important role in the physiology and pathology of the central nervous system. Exosomes may also have diagnostic and therapeutic potential in the brain.¹³

Exosomes and the $A\beta$ Pathology in the Central Nervous System

The contribution of exosomes to neurodegenerative disorders, like Alzheimer's disease (AD) involving $A\beta$ pathology has been summarized in several reviews.^{10,14,15} $A\beta$ enclosed in exosomes was hypothesized to take part in a prion-like propagation of $A\beta$ / $A\beta$ deposits.¹⁶ They were proposed to serve as an early diagnostic tool, as it was reported that $A\beta$ 1-42 levels, together with phospho-tau, in blood exosomes of neural origin predicted AD up to 10 years before onset.¹⁷

There are conflicting opinions on the role of exosomes in the $A\beta$ pathology in AD. On one hand, serum exosome levels were

correlated with increased amyloid plaque burden in an AD 5XFAD mouse model,¹⁸ and inhibition of exosome secretion by the nSMase2 inhibitor GW4869 reduced amyloid plaque formation *in vivo* in the same mouse model.¹⁹ Exosomes were nicknamed the ‘Trojan horse’ of neurodegenerative diseases carrying A β and transferring A β easily to other cells.²⁰ On the other hand neuroblastoma-derived exosomes injected into another AD-model mouse brain took up A β , leading to reduced A β levels, lower amyloid depositions, and decreased A β -mediated synaptotoxicity in the hippocampus. This suggested a role for neuroblastoma cell exosomes in A β clearance.²¹ Similar findings were also described for neuron-derived exosomes.²²

ECV from Peripheral Endothelial Cells

ECV originating from peripheral endothelial cells were assigned diverse functions and were shown to have different cargo molecules. For instance, endothelial ECV secreted from activated or apoptotic endothelial cells may participate both in harmful or beneficial events of the vascular endothelial response. These responses may include coagulation/anticoagulation, inflammation/anti-inflammatory effects, angiogenesis, endothelial survival, and regeneration. Therefore, these micro-particles may have a dual role in vascular homeostasis.²³ It was also demonstrated that human cytomegalovirus infected human umbilical vein endothelial cells (HUVEC) secreted exosomes that were immunogenic, possibly playing a role in immune surveillance.²⁴

Peripheral endothelial ECV cargo content can be very diverse. Among these cargo molecules, secretion of HSP70 via exosomes from rat aortic endothelial cells was demonstrated.²⁵ In another report, ECV released by HUVEC undergoing apoptosis and autophagy were enriched with autophagosomes and mitochondria, containing HSP60, HSP90, S100A8, and ATP. It was suggested that these ECV could be involved in the modulation of innate immunity.²⁶ ECV originating from HUVEC may contain angiopoietin-2, which is involved in the regulation of vascular integrity and inflammation.²⁷ When HUVEC were treated with chemotherapeutic agents, more exosomes were released containing miR-503, which exert antitumor activity by diminishing breast cancer cell proliferation and invasion.²⁸ This pointed to the therapeutic potential of endothelial exosomes. Neprilysin was also postulated to be released from endothelial cells via exosomes.²⁹ In addition, human dermal microvascular endothelial cells selectively sequestered cytoplasmic RNA-degrading machineries in exosomes, which may be involved in gene regulation.³⁰

It is interesting that the cargo type may change upon stimuli. For instance, when human dermal microvascular endothelial cells were exposed to different types of cellular stress, the secreted exosome protein and RNA content changed depending on the stress factor as evidenced by microarray analysis and a quantitative proteomics approach. This suggested that endothelial exosomes

might transfer stress factors to the target cells by this unique communication system.³¹

Although these studies do not specifically report on BBB relevance, we may assume that ECV originating from peripheral endothelial cells can cross the BBB and deliver their cargo into the central nervous system (CNS).

ECV as Drug Carriers into the CNS

The idea of using ECV from different cell types as carriers for various cargo molecules including drugs in the treatment of CNS diseases has been explored in the field. It was demonstrated that autologous exosomes (derived from dendritic cells) can be targeted to deliver siRNA to neurons, microglia, and oligodendrocytes of the mouse brain. The intravenously injected exosomes contained glyceraldehyde-3-phosphate dehydrogenase (GAPDH) siRNA and a specific knockdown of the GAPDH gene in the brain was achieved. Moreover, the therapeutic potential of the exosome-based delivery system was demonstrated in delivering the APP cleaving enzyme (BACE1) siRNA, resulting in downregulation of the BACE1 protein. In these experiments, exosomes represented a safe and efficient delivery tool by crossing the BBB noninvasively and without being immunogenic.³² Exosomes were also used for treatment of brain inflammatory diseases. Specifically, intranasally injected curcumin-loaded exosomes from different cell types were capable of inhibiting brain inflammation and autoimmune responses in a model of experimental autoimmune encephalomyelitis. Treatment with exosomes loaded with the Stat3 inhibitor JSI-124 resulted in delayed tumor growth in a model of glioblastoma. In both cases, the drugs enclosed in exosomes and administered via the intranasal route reached the brain rapidly and showed effectiveness.³³ Recently, exosomes derived from endothelial cells were also demonstrated to be suitable for various cargo delivery *in vitro*. For example, exosomes from primary aortic endothelial cells were reported to successfully deliver siRNA against luciferase into endothelial cells in a gene-silencing study.³⁴ However, additional studies are needed to explore if endothelial ECV can successfully deliver different cargo molecules into the brain as well.

Brain Endothelial Cell-Derived ECV

While a lot of information is available on ECV from different cell types, including peripheral endothelial cells, only few reports are found in the literature regarding ECV derived from brain microvascular endothelial cells forming the BBB.

The first study mentioning brain endothelial ECV was published by Virgintino et al.³⁵ The authors observed a fascinating phenomenon in the developing human brain’s vascular system. Specifically, the tip endothelial cells of the sprouting microvessels emitted several long and spider-web like filopodia as revealed by immunofluorescence and confocal microscopy. These filopodia were “decorated” with endothelial microvesicles, which were tightly associated with these elongations and appeared to follow

them during the vessel sprouting. The authors speculated that these vesicles may contain signaling molecules and may be involved in cell-cell communication, and tip cell guidance to find the target cells during angiogenesis in the developing brain. They concluded that further studies would shed light on the content and role of these endothelial microvesicles. To the best of our knowledge, this paper was the first to describe microvesicles derived from human brain microvascular endothelial cells.

Soon after that, in 2013, a method for isolation and characterization of brain endothelial ECV gave more insight into their features.³⁶ The *in vitro* BBB model used in this case was represented by the immortalized human brain microvascular endothelial cells.³⁷ The authors proposed that BBB-derived ECV can potentially have different functions: they may contain BBB-specific biomarkers, may be communication tools among the different cell types of the neurovascular unit, and may cross the cells through receptor mediated transcytosis mechanism. In this work, two ultracentrifugation steps at 100,000 x g for 60 min at 4°C were used to isolate ECV and ECV signature profiles were characterized using mass spectrometry-based proteomics. A total of 1179 proteins were identified. More than 60 known markers of ECV have been described.³⁸ The majority of these markers (58 out of 65) including Alix, TSG101 and the tetraspanin proteins CD81 and CD9 and many other ExoCarta proteins (a large proteomics database of ECV from different human cells) were detected. 524 proteins were not found in ExoCarta suggesting that they may be specific for brain endothelial cells. 35% of these were cell-surface and 65% were intracellular proteins. The 1179 identified proteins were involved in biological processes like intracellular trafficking, signal transduction, cell adhesion, and cell motility. They included RNA/DNA-binding proteins, receptors, structural proteins and enzymes. The authors concluded that these ECVs can take part in cell-cell communication within or outside of the neurovascular unit.

Later, another paper described research results from mouse brain endothelial exosomes which when preincubated with

curcumin, demonstrated beneficial effects on endothelial dysfunction, like oxidative stress and increased permeability.³⁹ In these experiments, mouse brain endothelial cells were primed with curcumin for 72 h and exosomes were isolated from the cell culture media. Isolation ultracentrifugation was used at 100,000 x g for 1 h, followed by immunoprecipitation with exo-specific beads. The curcumin-primed exosomes alleviated hyperhomocysteinemia-induced brain endothelial dysfunction by diminishing oxidative stress, tight junction protein alterations, and endothelial permeability increase. These results suggested that BBB-derived exosomes may be used as therapeutic tools in BBB disturbances. Mouse brain endothelial cell line (bEND3)-derived exosomes were also shown to effectively deliver the anticancer drugs doxorubicin and paclitaxel across the BBB for the treatment of brain cancer in a zebrafish model, demonstrating the therapeutic potential in the treatment of CNS diseases.⁴⁰




Figure 1. Extracellular vesicles from human brain microvascular endothelial cells (HBMEC). **(A)** Live fluorescence imaging of HBMEC transiently transfected with pT-CYTO-RFP and pT-CD63-GFP to visualize the brain endothelial cell (red) secreting green fluorescent CD63 positive extracellular vesicles (ECV). Scale bar: 2 μ m. **(B)** HBMEC were transiently transfected with pT-CD63 GFP or pT-CD9 RFP. ECV were isolated from the cell culture media. Fluorescence microscopy images of isolated fluorescent ECV (CD63 GFP-green, upper panel; CD9 RFP-red, lower panel). Scale bar: 20 μ m. **(C)** Differential interference contrast (DIC) image of isolated ECV. Scale bar: 2 μ m.




Figure 2. Dynamic light scattering analysis of isolated ECV from HBMEC. HBMEC-derived ECV were isolated from the cell culture media. **(A)** Size distribution indicates several peaks with the sizes of 68.41 nm, 609.1 nm and 5213 nm. **(B)** Volume distribution: 50.1% of the volume is for particles of ~60 nm, 2.4% for particles of ~5000 nm, and 47.4% for particles with an average diameter of ~600 nm.

(Fig. 1B). Visualization of ECV by differential interference contrast (DIC) imaging is presented in Figure 1C.

The size and volume distribution of ECV/exosome isolates is determined by dynamic light scattering (DLS) technique. Using the described isolation techniques, the DLS measurements indicate that ECV/exosome pool is highly polydisperse and prone to aggregation. Here we present one example of such measurements. The first order result from a DLS experiment is an intensity distribution of particle sizes. Intensity distribution in this sample indicates several peaks with the sizes of 68.41 nm, 609.1 nm and 5213 nm (Fig. 2A). The intensity distribution can be converted by the software, using Mie theory, to a volume distribution or a distribution describing the relative proportion of multiple components in the sample based on their mass or volume. The conversion assumes that all particles are spherical, homogenous, with known optical properties and that

Because ECV are heterogeneous, several methods were proposed for their isolation. The methods have not been standardized and controversy exists about which isolation approach is most suitable.⁴¹ Therefore, it is important to take into account the isolation method when interpreting the results of individual research reports. In our laboratory, we use ExoQuickTC to isolate ECV/exosomes from the culture media of human brain microvascular endothelial cells (HBMEC).³⁷ Exosomes are traced with CD63-GFP and/or CD9-RFP fusion Cyto-Tracers from SBI Biosciences. The tetraspanin CD63 and CD9 proteins are common biomarkers for exosomes. Using the CD63 and CD9 Cyto-Tracer constructs, the transiently transfected HBMEC secrete green or red fluorescent vesicles. For better visualization of individual cells secreting glowing exosomes, a double transfection is used. By cotransfecting HBMEC with pT-CYTO RFP (which gives the cytoplasm red fluorescence) and pT CD63 GFP (exosome tracer resulting in CD63 specific green fluorescence) we can follow green fluorescent ECV/exosome secretion by live cell imaging. Using this procedure, green fluorescent CD63 positive vesicles with different sizes budding from the cells can be observed (Fig. 1A). Secreted CD63-positive (green) or CD9-positive (red) ECV/exosomes can also be observed in the cell culture media following isolation using ExoQuickTC. Isolated vesicles are fixed, mounted and imaged by fluorescence microscopy




Figure 3. Exogenous A β (1-40) HiLyte in HBMEC-derived ECV. HBMEC were exposed to 100 nM A β (1-40) HiLyte for 48 h, followed by ECV isolation from cell culture media. A β (1-40) HiLyte (green fluorescence) in the isolated ECV was visualized by fluorescence microscopy. The images show the green fluorescent A β (1-40) HiLyte associated with ECV of different sizes. Scale bar: 20 μ m.

there is no error in the intensity distribution. According to the relative volume percentages, the volume distribution in sample from **Figure 2A** indicates 3 peaks: 47.4% of the volume for particles with ~600 nm, 2.4% of the volume for particles with ~5000 nm. Interestingly, 50.1% of the total volume is made up by particles with an average diameter of ~60 nm, which is consistent with the size range of exosomes (**Fig. 2B**).

Because ECV/exosomes from other cell types were reported to be important players in the brain's A β pathology,^{18,19,21,22} we hypothesized that BBB-derived ECV could also contribute to this pathology. HBMEC were exposed to fluorescently labeled A β , specifically to 100 nM A β (1-40) HiLyte, for 48 h. ECV from the cell culture media were isolated using ExoQuickTC. An interesting phenomenon was observed as A β (1-40) HiLyte was associated with ECV of very different sizes. Surprisingly, not only smaller but also larger vesicles contained A β (1-40) HiLyte cargo as indicated by green fluorescence under fluorescence microscopy (**Fig. 3**). This suggests that BBB-derived different ECV, and not only exosomes, may have a role in distributing A β within the central nervous system.

Concluding Remarks

While limited literature data exist regarding ECV from the BBB, there is a critical need to understand this area better. BBB-

derived ECV may have a crucial role in the brain's physiological and pathological processes. For example, BBB-derived ECV of different sizes may carry and transfer A β among the neighboring cells of the neurovascular units, possibly leading to neurovascular dysfunction in the course of AD.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We would like to thank Dr. Emre Dikici from Dr. Sylvia Daunert's laboratory for his help with the DLS measurements.

Funding

Supported by NIH/NHLBI (HL126559), NIH/NIDA (DA039576 and DA027569), and NIH/NIMH (MH063022, MH098891). We acknowledge support from the Miami Center for AIDS Research (CFAR) at the University of Miami Miller School of Medicine funded by a grant (P30AI073961) from the National Institutes of Health (NIH).

References

- Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. *J Inher Metab Dis* 2013; 36:437-49; PMID:23609350; <http://dx.doi.org/10.1007/s10545-013-9608-0>
- Abbott NJ, Friedman A. Overview and introduction: the blood-brain barrier in health and disease. *Epilepsia* 2012; 53 Suppl 6:1-6; PMID:23134489; <http://dx.doi.org/10.1111/j.1528-1167.2012.03696.x>
- Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. *J Cereb Blood Flow Metab* 2013; 33:1500-13; PMID:23921899; <http://dx.doi.org/10.1038/jcbfm.2013.135>
- Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. *Curr Alzheimer Res* 2007; 4:191-7; PMID:17430246; <http://dx.doi.org/10.2174/156720507780362245>
- Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. *J Proteomics* 2010; 73:1907-20; PMID:20601276; <http://dx.doi.org/10.1016/j.jprot.2010.06.006>
- They C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 2009; 9:581-93; PMID:19498381; <http://dx.doi.org/10.1038/nri2567>
- Meckes DG, Jr, Raab-Traub N. Microvesicles and viral infection. *J Virol* 2011; 85:12844-54; PMID:21976651; <http://dx.doi.org/10.1128/JVI.05853-11>
- Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol* 2009; 19:43-51; PMID:19144520; <http://dx.doi.org/10.1016/j.tcb.2008.11.003>
- Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. *J Cell Biochem* 2010; 111:488-96; PMID:20533300; <http://dx.doi.org/10.1002/jcb.22733>
- Gupta A, Pulliam L. Exosomes as mediators of neuroinflammation. *J Neuroinflammation* 2014; 11:68; PMID:24694258; <http://dx.doi.org/10.1186/1742-2094-11-68>
- Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, They C, Raposo G. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. *J Cell Sci* 2013; 126:5553-65; PMID:24105262; <http://dx.doi.org/10.1242/jcs.128868>
- Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim Biophys Acta* 2012; 1820:940-8; PMID:22503788; <http://dx.doi.org/10.1016/j.bbagen.2012.03.017>
- Kawikova I, Askenase PW. Diagnostic and therapeutic potentials of exosomes in CNS diseases. *Brain Res* 2015; 1617:63-71; PMID:25304360; <http://dx.doi.org/10.1016/j.brainres.2014.09.070>
- Vella LJ, Sharples RA, Nisbet RM, Cappai R, Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. *Eur Biophys J* 2008; 37:323-32; PMID:18064447; <http://dx.doi.org/10.1007/s00249-007-0246-z>
- Kalani A, Tyagi A, Tyagi N. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. *Mol Neurobiol* 2014; 49:590-600; PMID:23999871; <http://dx.doi.org/10.1007/s12035-013-8544-1>
- Vingtdeux V, Sergeant N, Bue L. Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. *Front Physiol* 2012; 3:229; PMID:22783199; <http://dx.doi.org/10.3389/fphys.2012.00229>
- Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. *Alzheimers Dement* 2015; 11:600-7 e1; PMID:25130657; <http://dx.doi.org/10.1016/j.jalz.2014.06.008>
- Dinkins MB, Dasgupta S, Wang G, Zhu G, He Q, Kong JN, Bieberich E. The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden. *J Alzheimers Dis* 2015; 46:55-61; PMID:25720409; <http://dx.doi.org/10.3233/JAD-150088>
- Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. *Neurobiol Aging* 2014; 35:1792-800; PMID:24650793; <http://dx.doi.org/10.1016/j.neurobiolaging.2014.02.012>
- Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? *Front Physiol* 2012; 3:124; PMID:22563321; <http://dx.doi.org/10.3389/fphys.2012.00124>
- Yuyama K, Sun H, Sakai S, Mitsutake S, Okada M, Tahara H, Furukawa J, Fujitani N, Shinohara Y, Igarashi Y. Decreased amyloid- β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice. *J Biol Chem* 2014; 289:24488-98; PMID:25037226; <http://dx.doi.org/10.1074/jbc.M114.577213>
- Yuyama K, Sun H, Usuki S, Sakai S, Hanamatsu H, Mioka T, Kimura N, Okada M, Tahara H, Furukawa J, et al. A potential function for neuronal exosomes: sequestering intracerebral amyloid- β peptide. *FEBS Lett* 2015; 589:84-8; PMID:25436414; <http://dx.doi.org/10.1016/j.febslet.2014.11.027>
- Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. *HUVEC ECV* may also participate in immune surveillance. *Arterioscler Thromb Vasc Biol* 2011; 31(1):27-33; PMID:21160065; <http://dx.doi.org/10.1161/ATVBAHA.110.218123>
- Walker JD, Maier CL, Pober JS. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. *J Immunol* 2009; 182(3):1548-59;

- PMID:19155503; <http://dx.doi.org/10.4049/jimmunol.182.3.1548>
25. Zhan R, Leng X, Liu X, Wang X, Gong J, Yan L, Wang L, Wang Y, Wang X, Qian LJ. Heat shock protein 70 is secreted from endothelial cells by a non-classical pathway involving exosomes. *Biochem Biophys Res Commun* 2009; 387(2):229-33; PMID:19555663; <http://dx.doi.org/10.1016/j.bbrc.2009.06.095>
 26. Pallet N, Sirois I, Bell C, Hanafi LA, Hamelin K, Dieudé M, Rondeau C, Thibault P, Desjardins M, Hebert MJ. A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells. *Proteomics* 2013; 13(7):1108-20; PMID:23436686; <http://dx.doi.org/10.1002/pmic.201200531>
 27. Ju R, Zhuang ZW, Zhang J, Lanahan AA, Kyriakides T, Sessa WC, Simons M. Angiopoietin-2 secretion by endothelial cell exosomes: regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways. *J Biol Chem* 2014; 289(1):510-9; <http://dx.doi.org/10.1074/jbc.M113.506899>
 28. Bovy N, Blomme B, Frères P, Dederen S, Nivelles O, Lion M, Carnet O, Martial JA, Noël A, Thiry M, et al. Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. *Oncotarget*. 2015; 6(12):10253-66; PMID:25860935; <http://dx.doi.org/10.18632/oncotarget.3520>
 29. Kuruppu S, Rajapakse NW, Minond D, Smith AI. Production of soluble neprilysin by endothelial cells. *Biochem Biophys Res Commun* 2014; 446(2):423-7; PMID:24495806; <http://dx.doi.org/10.1016/j.bbrc.2014.01.158>
 30. van Balkom BW, Eisele AS, Pegtel DM, Bervoets S, Verhaar MC. Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting. *J Extracell Vesicles* 2015; 4:26760; PMID:26027894
 31. de Jong OG, Verhaar MC, Chen Y, Vader P, Gremmels H, Posthuma G, Schifflers RM, Gucek M, van Balkom BW. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. *J Extracell Vesicles* 2012; 1: 18396; PMID:24009886
 32. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhai S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol* 2011; 29:341-5: 24858; PMID:21423189; <http://dx.doi.org/10.1038/nbt.1807>
 33. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs to the nasal region to the brain. *Mol Ther* 2011; 19:1769-79; PMID:21915101; <http://dx.doi.org/10.1038/mt.2011.164>
 34. Banizs AB, Huang T, Dryden K, Berr SS, Stone JR, Nakamoto RK, Shi W, He J. In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery. *Int J Nanomedicine* 2014; 9:4223-30; PMID:25214786
 35. Virgintino D, Rizzi M, Errede M, Strippoli M, Girolamo F, Bertossi M, Roncali L. Plasma membrane-derived microvesicles released from tip endothelial cells during vascular sprouting. *Angiogenesis* 2012; 15:761-9; PMID:22886085; <http://dx.doi.org/10.1007/s10456-012-9292-y>
 36. Haqqani AS, Delaney CE, Tremblay TL, Sodja C, Sandhu JK, Stanimirovic DB. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. *Fluids Barriers CNS* 2013; 10:4; PMID:23305214; <http://dx.doi.org/10.1186/2045-8118-10-4>
 37. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. *FASEB J* 2005; 19:1872-4; PMID:16141364
 38. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. *Proteomics* 2008; 8:4083-99; PMID:18780348; <http://dx.doi.org/10.1002/pmic.200800109>
 39. Kalani A, Kamat PK, Chaturvedi P, Tyagi SC, Tyagi N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. *Life Sci* 2014; 107:1-7; PMID:24780320; <http://dx.doi.org/10.1016/j.lfs.2014.04.018>
 40. Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. *Pharm Res* 2015; 32(6):2003-14; <http://dx.doi.org/10.1007/s11095-014-1593-y>
 41. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, Bracke M, De Wever O, Hendrix A. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. *J Extracell Vesicles* 2014; 3: 24858; PMID:25317274